Safety and Efficacy of Different Add Powers With a New Presbyopic Lasik Treatment Algorithm - Trial NCT04617080
Access comprehensive clinical trial information for NCT04617080 through Pure Global AI's free database. This phase not specified trial is sponsored by Bausch & Lomb Incorporated and is currently Recruiting. The study focuses on Ametropia. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Bausch & Lomb Incorporated
Timeline & Enrollment
N/A
Jan 26, 2021
Nov 01, 2022
Primary Outcome
Binocular Uncorrected Distance Visual Acuity (UDVA)
Summary
This is a prospective, comparative, randomized, controlled, open-label, single-surgeon,
 single-center PMCF clinical study whereby presbyopic patients undergoing refractive surgery
 will receive a SUPRACOR treatment for the correction in the non-dominant eye and a PROSCAN
 refractive treatment in the dominant eye to correct for ametropia.
 
 The participants will be randomized to either a SUPRACOR regular (100%) or SUPRACOR strong
 (130%) treatment with a 1:1 ratio.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04617080
Non-Device Trial